Lineage Cell Therapeutics, Inc. cotiza a 0.91 USD y tiene una capitalización bursátil de $231M. En los últimos 12 meses ha facturado $13M con un margen de flujo de caja libre del -133.6%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical tria…
| Periodo | 2026-11 | 2026-08 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | — | $0.01 | — | $-0.13 |
| Estimado | $-0.04 | $-0.03 | $-0.04 | $-0.03 |
| Sorpresa | — | +133.3% | — | -333.3% |
| Métrica | LCTX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -251.6% | -38.6% | -212.9% |
| Net Margin | -436.5% | -33.6% | -402.9% |
| FCF Margin | -133.6% | -13.9% | -119.7% |
| ROE | -142.6% | -40.4% | -102.2% |
| ROA | -56.4% | -32.0% | -24.4% |
| Current Ratio | 5.20 | 2.84 | +2.36 |
| Debt / Equity | — | 0.28 | — |